Medicago Inc.

Immunovaccine Technologies Inc.

Biovaxys Inc.

Frederic Ors

Marc-Andre D'Aoust

Pierre-Olivier Lavoie

Manon Couture

Nathalie Landry

Michele Dargis

Louis-Philippe Vezina

Leeladhar Sammatur

Sonia Trepanier

Marc Mansour

Lisa Diana MacDonald

Marianne Michelle Stanford

Rajkannan Rajagopalan

Genevieve Mary Weir

Louis-Philippe Vézina

Sonia Trépanier

Marianne Stanford

The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 μl and induces an antibody immune response to the B-cell epitope in the human subject.

Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.

Recombinant influenza virus-like particles (VLPS) produced in transgenic plants

The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 &#x3bc;l and induces an antibody immune response to the B-cell epitope in the human subject.

The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.

Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof

Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin

Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant

Growing community of inventors

CA

Frederic Ors